• ReVision Optics

  Participated · Equity · Nov 2016

  ReVision Optics develops and commercializes the Raindrop Near Vision Inlay, an implantable device placed in the cornea of the non-dominant eye to correct presbyopia. The Raindrop is a transparent, approximately 80% water inlay with a refractive index similar to the cornea that reshapes anterior corneal curvature to improve near vision during a roughly 10-minute procedure. Raindrop received U.S. FDA approval on June 29, 2016, and the first U.S. commercial cases were performed on August 30, 2016; it has also received CE Mark authorization and approvals or registrations in South Korea, Australia, and New Zealand. Since the U.S. launch, more than 100 surgeons have scheduled cases, and the company initially focused launch sites that participated in the IDE clinical trial. Proceeds from the company's recent $32 million equity financing will support expansion of U.S. commercialization, including a larger commercial field organization, expanded marketing, and a strengthened medical affairs team. ReVision plans to train more surgeons on the Raindrop procedure and expand contact with additional ophthalmologists as it rolls out nationally. ReVision Optics focuses on the development and commercialization of the Raindrop Near Vision Inlay, an implantable device that reshapes the anterior corneal curvature to improve near vision. The Raindrop Inlay is composed of approximately 80% water, is transparent, and is placed in the non-dominant eye during a brief procedure. The device has received U.S. FDA approval (granted June 29, 2016), CE Mark authorization for the EU, and approvals or registrations in South Korea, Australia, and New Zealand, with other country-specific registrations pending. The company is building commercial infrastructure in advance of a U.S. launch scheduled for late this month. To support commercialization and working capital needs, ReVision Optics has secured external financing. The company is headquartered in Lake Forest and San Diego, California. ReVision Optics develops and commercializes the Raindrop Near Vision Inlay, a microscopic hydrogel inlay designed to correct presbyopia by microscopically reshaping the anterior corneal curvature. The Raindrop is placed beneath the surface of the non-dominant eye in a brief procedure, is ~80% water with a refractive index similar to the cornea, and is intended to restore near and intermediate vision without restricting light to the retina. The company recently completed patient enrollment in its U.S. IDE clinical trial evaluating the Raindrop's safety and effectiveness. ReVision says the new financing provides the resources to carry it through the FDA PMA process and to expand its commercial footprint outside the U.S. As part of its commercialization strategy, the company has a commercial supply and distribution agreement with NovaMedica (a partnership of Domain Associates and Rusnano) to commercialize Raindrop in Russia and the CIS. The $55 million financing strengthens the company's financial position to support regulatory and international commercialization efforts. ReVision Optics is a Lake Forest, CA-based ophthalmic surgical products company that specializes in the research, development and manufacturing of custom products to correct and maintain near vision. Its core product is the PresbyLens® corneal inlay for the correction of presbyopia. This spring the company began US clinical trials to evaluate the PresbyLens by studying 400 patients over a two-year period. ReVision Optics is actively pursuing regulatory approvals and market opportunities worldwide. The company holds a CE mark and is approved for sale in Europe. It received $35M in capital funding to support its development and commercialization efforts.

• Mevion Medical Systems

  Participated · Equity · Aug 2015

  Mevion develops and sells compact proton therapy systems, including the HYPERSCAN™ pencil beam scanning solution that uses the Adaptive Aperture™ proton MLC. The company positions HYPERSCAN as a breakthrough in proton therapy and already has clinical use at MedStar Georgetown University Hospital, with installations at an NCI‑Designated Cancer Center in the U.S. and the MAASTRO Clinic in the Netherlands. Mevion reports strong commercial interest in the United States and Europe and is negotiating additional units in Asia, with two additional centers in final design. The $150 million financing will be used to further distance Mevion’s technological leadership, expand manufacturing capacity to meet increased interest, and support expansion into emerging markets and the Asia Pacific region. The transaction also clears existing debt and optimizes the shareholder structure. The new and existing investor group collectively manages over $10 billion in assets, providing a long‑term capital base. Mevion Medical Systems is a leading provider of proton therapy systems whose flagship product is the MEVION S250, the only modular single‑room proton therapy system currently on the market. The MEVION S250 delivers targeted radiation therapy at a fraction of the size, operating costs and energy use of legacy systems, with a single‑room footprint of about 2,000 sq. ft. and high operational efficiency. Mevion has installed systems at Barnes‑Jewish Hospital, Ackerman Cancer Center, and Robert Wood Johnson University Hospital and achieved rapid patient ramp‑up (first 100 patients in 11 months; ACC reached 350 patients/year in under three months; RWJ treated its first patient less than four weeks after ACC). The company is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. Mevion announced an investment agreement for up to $200 million to accelerate worldwide expansion and to increase manufacturing capacity and global service capability to support new installations in the U.S., China and internationally. Concurrent with the investment, Mevion and the lead investors will form a joint venture in China to produce, sell and service proton therapy systems for the Chinese market. Mevion Medical Systems develops and supplies the MEVION S250, a single-room proton therapy system designed to deliver precise radiation with a reduced size and lower implementation cost compared with legacy proton systems. The MEVION S250 preserves the clinical benefits of traditional proton therapy while offering improved reliability, efficient clinical workflow, and a footprint similar to modern X-ray radiation therapy devices. The system is FDA-cleared for clinical use and the first MEVION S250 is installed at the S. Lee Kling Center for Proton Therapy at Barnes Jewish Hospital/Washington University Medical Center, currently undergoing clinical acceptance and commissioning. Mevion reports five centers under installation and construction and more than a dozen centers under planning, positioning the company for wider deployment. The company says its technology makes proton therapy more accessible and practical for hospitals and patients, including pediatric and high‑risk cases. To support this expansion, Mevion has raised additional capital to accelerate deployment of the MEVION S250 in the U.S. and internationally. Mevion Medical Systems is the developer of the MEVION S250 Proton Therapy System, a compact proton beam radiation device powered by a TriNiobium Core designed to reduce cost, size and complexity compared with traditional proton systems. The company says the S250 preserves the treatment benefits of proton therapy while improving accessibility and practicality for wider clinical deployment. Mevion has delivered its first system and has two additional systems under installation. The MEVION S250 had not yet been cleared by the U.S. FDA for clinical use at the time of the announcement. The company announced a $45 million investment to accelerate manufacturing and worldwide deployment of the S250. Mevion was founded in 2004 and is headquartered in the Boston metropolitan area, with international offices in the United Kingdom and Japan.

• Immune Design

  Participated · Series C · Oct 2013

  Immune Design is a Seattle, WA-based clinical-stage biotechnology company that develops immune-based therapies for cancer, infectious diseases, allergy, and autoimmune disorders. The company builds two synergistic platforms: DCVex™, a lentiviral vector platform delivering antigen-encoding nucleic acids to dendritic cells in vivo, and GLAAS™, a TLR4 agonist platform that activates dendritic cells and promotes Th1 cytokine responses. Its lead therapeutic candidates are ID-LV305 (from DCVex™) and ID-G305 (leveraging GLAAS™), which are investigational cancer therapeutics designed to elicit tumor-specific T cell and broader immune responses. Immune Design intends to advance these candidates through proof-of-concept studies and to initiate clinical trials of each as single agents, as a combined candidate (ID-CMB305), and in combination with other cancer immunotherapy approaches. The company is led by Carlos Paya, M.D., Ph.D., as President and CEO, with senior clinical and scientific leadership guiding development. Immune Design Corp. is a Seattle, WA–based biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer. It is advancing a vaccine pipeline built on two proprietary technologies: GLA, a synthetic TLR-4 agonist clinical-stage adjuvant, and DC-NILV, a delivery vector engineered to target human dendritic cells and express antigens and immunomodulatory elements. GLA is being developed as a component in multiple internal and partnered vaccine programs. DC-NILV is initially being applied in cancer indications of significant unmet need. The company plans to use new funds to accelerate lead candidates through clinical studies and to expand development of new vaccines and therapeutics. Since its inception in 2008 Immune Design has raised $50M in equity capital to date.

• Mersana Therapeutics

  Participated · Series A · Jul 2012

  Mersana Therapeutics is a Cambridge, MA‑based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). It is advancing a proprietary Fleximer® immunoconjugate platform under the leadership of President and CEO Anna Protopapas. The company completed a $33M Series C financing to support further development of its pipeline programs and to expand its ADC platform. The Series C was led by Wellington Management Company with participation from Cormorant Asset Management, Arrowpoint Partners, Takeda Pharmaceutical Company Limited and existing investors New Enterprise Associates and Rock Springs Capital. Mersana anticipated filing an IND for its lead candidate XMT-1522, a novel HER‑2 targeting therapy, in mid‑2016 and planned to initiate a Phase 1 proof‑of‑concept trial shortly thereafter. Its second program, XMT-1536, a novel anti‑NaPi2b ADC, was advancing into IND‑enabling studies. Mersana Therapeutics engineers next-generation Fleximer antibody-drug conjugates (ADCs) built on a proprietary biodegradable polymer system designed to increase drug loading and enable diverse payloads. Its Fleximer platform uses specialized linker systems and includes proprietary payload platforms named Dolaflexin, Vindeflexin, and Cytoflexin. The company is advancing a pipeline of Fleximer-ADCs with select pharmaceutical partners while progressing internal programs toward clinical development. Mersana announced a $35 million Series B-1 financing to fund advancement of its pipeline, with its first IND filing anticipated later this year. The financing coincided with management changes, including the appointment of Anna Protopapas as President and CEO and the addition of Elaine V. Jones to the board. Mersana is based in Cambridge, Mass. Mersana Therapeutics, led by President and CEO Nicholas Bacopoulos, Ph.D., develops an antibody‑drug conjugate (ADC) platform called Fleximer® and a pipeline of small molecule conjugates. The Fleximer® platform enables attachment and controlled release of a broad range of anti‑tumor payloads. The company is advancing two small molecule conjugates: XMT-1001, a novel “tecan” conjugate in a Phase 1b extension trial in patients with lung cancers, and XMT-1107, an anti‑angiogenic conjugate in a Phase 1 trial in patients with refractory, advanced solid tumors. XMT-1107 was licensed to Teva Pharmaceutical Industries Ltd. on a worldwide basis except for Japan, where Mersana retained rights. Mersana intends to use the financing proceeds to advance its ADC technology and to generate a pipeline of proprietary next‑generation ADCs. The company recently raised capital to support continued clinical development of its lead candidates.

• Agile Therapeutics

  Participated · Series C · Jul 2012

  Agile Therapeutics, Inc. announced that it secured $45 million in funding from Perceptive Advisors LLC. The company amended the terms of the transaction on March 1, 2021. Following that amendment, the transaction total stood at $45 million. Perceptive Advisors provided an additional $10 million in its fourth tranche close. The financing was completed in multiple tranches, with the fourth tranche bringing in the $10 million contribution. The announcement did not disclose instruments, operating metrics, products, prior rounds, founding year, or location. Agile Therapeutics develops transdermal contraceptive patches and proprietary Skinfusion® delivery technology for stable seven-day drug delivery and adhesion. Its lead product, AG200-15, is a once-weekly contraceptive patch for which Agile filed a New Drug Application (NDA) with the FDA and expects a response in Q1 2013. The company is also developing a progestin-only contraceptive patch, AG890. Agile intends to use the new capital to support pre-launch and launch activities for AG200-15 and to continue development of AG890. The company is led by President and CEO Al Altomari. In conjunction with the financing, Dr. Andrew Schiff of Aisling Capital joined Agile’s board. Agile Therapeutics is a late-stage pharmaceutical company focused on women’s healthcare and developing transdermal contraceptive patches. Its lead product is the AG200-15 contraceptive patch, and the company is also developing a second patch, AG1000. Agile is completing Phase 3 clinical development for AG200-15 and preparing to file for marketing approval. The company plans to advance AG1000 into Phase 2 clinical development and to develop additional pipeline products based on its SKINFUSION™ technology. Agile’s patches are being developed to provide women with a convenient and easy-to-use alternative to their current means of contraception. The company completed a $45M Series B financing to fund these development plans.

No current team members are available.